Septerna, Inc. Overview
Pro stress-test →Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. The company's proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas.
Strategic Profile
Pro stress-test →The company has a global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Analyst sentiment remains bullish with eight buy ratings and no hold or sell ratings, with an average target price of $33.86 indicating potential upside of 11.81% from current levels.
Competitive Landscape
Pro stress-test →Septerna focuses on developing GPCR oral small molecule products targeting endocrinology, immunology, inflammation, and metabolic disorders. The company competes in the clinical-stage biotech space against other GPCR-focused platforms and larger pharma companies developing therapies in metabolic and immunology indications. Its Novo Nordisk partnership validates its proprietary platform approach and provides significant capital advantage over most competitors.
Industry Context
Septerna, Inc. operates in Biotechnology - Clinical Stage GPCR Drug Discovery.
Key facts
Founded: 2019 · Headquarters: South San Francisco, California · Employees: 200-300 · Revenue: $15M-20M · Market cap: $1.32B